Q3 2019 Investor Presentation slide image

Q3 2019 Investor Presentation

Propeller has demonstrated compelling clinical outcomes i Impact of the Propeller solution tracking inhaler usage and location SABA use over time Symptom free days Healthcare utilization # per day % Events -25% 79 2.0 +32% 75 1.5 -50% 50 50 1.0 25 0.5 Uncontrolled 0.0 COPD 0 50 100 150 Uncontrolled Asthma Drives a decrease in medication Adherence % 59 0 200 0 50 100 150 200 Before After Drives an improvement in Drives a reduction in healthcare utilization QOL QoL: Rescue Inhaler use per day Acute care utilization # times used Events per 100 patient years 1.5 Pre-enrollment 13 12 Post-enrollment +58% 57 1.0 36 -75% 0.5 0.0 Control Intervention 1 Drives an 180 Drives an improvement in improvement in ©2019 ResMed I Q3 2019 Investor Presentation | 23 adherence QOL 6 5 2 0 365 ED + Hosp. ED Hosp. Drives a reduction in healthcare utilization ResMed
View entire presentation